SCHEMBL8418459

SCHEMBL8418459

O=C(O)c1c(-c2ccccc2)ccc2cc3ccccc3cc12

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.56
MEN1 O00255 4/20 0.56
KMT2A Q03164 4/20 0.56
ALDH1A1 P00352 3/20 0.56
CYP1A2 P05177 3/20 0.56
CYP2C19 P33261 3/20 0.56
HPGD P15428 2/20 0.56
HSD17B10 Q99714 2/20 0.56
GLA P06280 1/20 0.56
MAPT P10636 2/20 0.43
MPI P34949 1/20 0.43
GAA P10253 1/20 0.42
SOS1 Q07889 2/20 0.41
HIF1A Q16665 2/20 0.41
TP53 P04637 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
FOLH1 Q04609 2/20 0.41
GPR84 Q9NQS5 3/20 0.40
ACMSD Q8TDX5 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28539802 0.87 KDM4E (0.51) KDM4EMEN1KMT2AALDH1A1CYP1A2
SCHEMBL1195261 0.84 MEN1 (0.57) KDM4EMEN1KMT2AALDH1A1CYP1A2
SCHEMBL11351560 0.83 AKR1C3 (0.44) KDM4EMEN1KMT2AALDH1A1CYP1A2
SCHEMBL28328296 0.81 ALOX5 (0.52) KDM4EMEN1KMT2AALDH1A1HPGD
SCHEMBL29506855 0.79 KDM4E (0.60) KDM4EMEN1KMT2AALDH1A1CYP1A2
SCHEMBL929603 0.79 ALDH1A1 (0.60) KDM4EMEN1KMT2AALDH1A1CYP1A2
SCHEMBL43510 0.79 KDM4E (0.60) KDM4EMEN1KMT2AALDH1A1CYP1A2
SCHEMBL11363544 0.79 ALDH1A1 (0.47) KDM4EMEN1KMT2AALDH1A1CYP1A2
SCHEMBL8834901 0.79 NPC1 (0.54) KDM4EMEN1KMT2AALDH1A1CYP1A2
SCHEMBL4896934 0.78 ALDH1A1 (0.84) KDM4EMEN1KMT2AALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3946480-A1 TWO-COMPONENT SYSTEM FOR THE THERAPEUTIC TREATMENT OF SKIN LESIONS AND PRODUCTION METHOD THEREOF DTech - Società a Responsabilità Limitata (IT) 2022-02-09 EP claimed
WO-2020201940-A1 TWO-COMPONENT SYSTEM FOR THE THERAPEUTIC TREATMENT OF SKIN LESIONS AND PRODUCTION METHOD THEREOF DTECH - SOCIETÀ A RESPONSABILITÀ LIMITATA (IT) 2020-10-08 WO claimed
EP-0550006-B1 Use of N-acyl derivatives of aminoalcohols for the manufacture of a medicament for the treatment of pathologies involving mast cells LIFEGROUP SPA (IT) 1999-09-08 EP claimed
EP-0751947-B1 GLUCOSIDIC DERIVATIVES OF N-ACYL ALKYLAMINES EXERTING NEUROPROTECTIVE, NEUROTROPHIC AND ANTI-INFLAMMATORY ACTION, USEFUL IN ACUTE AND CHRONIC DISORDERS OF THE CENTRAL NERVOUS SYSTEM CONNECTED WITH EXCITOTOXICITY LIFEGROUP SPA (IT) 1998-08-12 EP claimed
US-5506224-A ADMINISTERING TO TREAT MAMMALIAN PATHOLOGIES INVOLVING MAST CELL DEGRANULATION AS CONSEQUENCE OF NEUROGENIC AND/OR IMMUNOGENIC HYPERSTIMULATION LIFEGROUP S.P.A. (IT) 1996-04-09 US claimed
EP-0550006-A2 Use of N-acyl derivatives of aminoalcohols for the manufacture of a medicament for the treatment of pathologies involving mast cells LIFEGROUP S.p.A. (IT) 1993-07-07 EP claimed
EP-0325061-A2 Process for producing poly (para-phenylene-sulfide) Tosoh Corporation (JP) 1989-07-26 EP claimed
US-5506224-A ADMINISTERING TO TREAT MAMMALIAN PATHOLOGIES INVOLVING MAST CELL DEGRANULATION AS CONSEQUENCE OF NEUROGENIC AND/OR IMMUNOGENIC HYPERSTIMULATION LIFEGROUP S.P.A. (IT) 1996-04-09 US disclosed
US-4542183-A Fatigue crack growth retardant material LOCKHEED CORPORATION (US) 1985-09-17 US disclosed